Suven Life Sciences announced positive results from its Phase 2a proof-of-concept study of Ropanicant (SUVN-911) in patients with moderate to severe Major Depressive Disorder (MDD).
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.